JP2019511471A5 - - Google Patents

Download PDF

Info

Publication number
JP2019511471A5
JP2019511471A5 JP2018543209A JP2018543209A JP2019511471A5 JP 2019511471 A5 JP2019511471 A5 JP 2019511471A5 JP 2018543209 A JP2018543209 A JP 2018543209A JP 2018543209 A JP2018543209 A JP 2018543209A JP 2019511471 A5 JP2019511471 A5 JP 2019511471A5
Authority
JP
Japan
Prior art keywords
seq
oligonucleotide
compound
vrna
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018543209A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019511471A (ja
JP7536272B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/020241 external-priority patent/WO2017151795A1/en
Publication of JP2019511471A publication Critical patent/JP2019511471A/ja
Publication of JP2019511471A5 publication Critical patent/JP2019511471A5/ja
Priority to JP2022162516A priority Critical patent/JP2022176378A/ja
Application granted granted Critical
Publication of JP7536272B2 publication Critical patent/JP7536272B2/ja
Priority to JP2025061328A priority patent/JP2025096365A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018543209A 2016-03-02 2017-03-01 インフルエンザウイルスに対する汎遺伝子型薬剤及びその使用方法 Active JP7536272B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022162516A JP2022176378A (ja) 2016-03-02 2022-10-07 インフルエンザウイルスに対する汎遺伝子型薬剤及びその使用方法
JP2025061328A JP2025096365A (ja) 2016-03-02 2025-04-02 インフルエンザウイルスに対する汎遺伝子型薬剤及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662302548P 2016-03-02 2016-03-02
US62/302,548 2016-03-02
PCT/US2017/020241 WO2017151795A1 (en) 2016-03-02 2017-03-01 Pan-genotypic agents against influenza virus and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022162516A Division JP2022176378A (ja) 2016-03-02 2022-10-07 インフルエンザウイルスに対する汎遺伝子型薬剤及びその使用方法

Publications (3)

Publication Number Publication Date
JP2019511471A JP2019511471A (ja) 2019-04-25
JP2019511471A5 true JP2019511471A5 (cg-RX-API-DMAC7.html) 2020-03-19
JP7536272B2 JP7536272B2 (ja) 2024-08-20

Family

ID=59743201

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018543209A Active JP7536272B2 (ja) 2016-03-02 2017-03-01 インフルエンザウイルスに対する汎遺伝子型薬剤及びその使用方法
JP2022162516A Withdrawn JP2022176378A (ja) 2016-03-02 2022-10-07 インフルエンザウイルスに対する汎遺伝子型薬剤及びその使用方法
JP2025061328A Pending JP2025096365A (ja) 2016-03-02 2025-04-02 インフルエンザウイルスに対する汎遺伝子型薬剤及びその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022162516A Withdrawn JP2022176378A (ja) 2016-03-02 2022-10-07 インフルエンザウイルスに対する汎遺伝子型薬剤及びその使用方法
JP2025061328A Pending JP2025096365A (ja) 2016-03-02 2025-04-02 インフルエンザウイルスに対する汎遺伝子型薬剤及びその使用方法

Country Status (17)

Country Link
US (1) US10597658B2 (cg-RX-API-DMAC7.html)
EP (3) EP4389221A3 (cg-RX-API-DMAC7.html)
JP (3) JP7536272B2 (cg-RX-API-DMAC7.html)
CN (1) CN108778344A (cg-RX-API-DMAC7.html)
CA (1) CA3014776A1 (cg-RX-API-DMAC7.html)
DK (1) DK3800257T3 (cg-RX-API-DMAC7.html)
ES (1) ES2981765T3 (cg-RX-API-DMAC7.html)
FI (1) FI3800257T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240765T1 (cg-RX-API-DMAC7.html)
HU (1) HUE066977T2 (cg-RX-API-DMAC7.html)
LT (1) LT3800257T (cg-RX-API-DMAC7.html)
PL (1) PL3800257T3 (cg-RX-API-DMAC7.html)
PT (1) PT3800257T (cg-RX-API-DMAC7.html)
RS (1) RS65707B1 (cg-RX-API-DMAC7.html)
SI (1) SI3800257T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400253T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017151795A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11339392B2 (en) 2016-03-02 2022-05-24 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against influenza virus and methods of using the same
WO2021201996A1 (en) * 2020-02-14 2021-10-07 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against respiratory viruses and methods of using the same
US12522827B2 (en) 2016-03-02 2026-01-13 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against influenza virus and methods of using the same
CN115997014A (zh) * 2020-02-14 2023-04-21 小利兰·斯坦福大学董事会 抗呼吸道病毒的泛基因型药剂及其使用方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06501843A (ja) * 1990-08-14 1994-03-03 アイシス・ファーマシューティカルス・インコーポレーテッド アンチセンスオリゴヌクレオチドによるインフルエンザa型ウイルス,アン・アーバh2n2株の阻害
US20040242518A1 (en) 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
US8357664B2 (en) 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
CA2603842A1 (en) * 2005-04-08 2006-10-19 Nastech Pharmaceutical Company Inc. Rnai therapeutic for respiratory virus infection
EP2239328A3 (en) * 2005-08-18 2011-01-05 Alnylam Pharmaceuticals Inc. Methods and compositions for treating neurological disease
CN100562342C (zh) * 2006-01-17 2009-11-25 奥林格斯技术有限公司 防治流感病毒感染的寡核苷酸药物
WO2007084359A2 (en) * 2006-01-17 2007-07-26 Oligos Etc., Inc. Compositions and methods for the treatment of influenza infection
AU2007310982A1 (en) * 2006-10-18 2008-04-24 Marina Biotech, Inc. Nicked or gapped nucleic acid molecules and uses thereof
US20090042823A1 (en) 2007-08-10 2009-02-12 Mdrna, Inc. Uses of broad spectrum rnai therapeutics against influenza
US20120003156A1 (en) 2008-07-01 2012-01-05 The Johns Hopkins University Methods for treating neoplasia by inhibiting lactate dehydrogenase and/or nicotinamide phosphoribosyltransferase
SI2607484T1 (sl) 2008-10-27 2016-11-30 Biomarin Technologies B.V. Metode in sredstva za učinkovito preskakovanje eksona 45 v pre-mRNA Duchennove mišične distrofije
AU2010319314C1 (en) * 2009-11-13 2016-09-01 Sarepta Therapeutics, Inc. Antisense antiviral compound and method for treating influenza viral infection
US8921334B2 (en) 2009-12-29 2014-12-30 Curna, Inc. Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1
CN103118694B (zh) 2010-06-01 2016-08-03 Atyr医药公司 与赖氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现

Similar Documents

Publication Publication Date Title
Pariente et al. Efficient virus extinction by combinations of a mutagen and antiviral inhibitors
Bracho et al. Contribution of Taq polymerase-induced errors to the estimation of RNA virus diversity
Morshed et al. Fowl adenoviruses D and E cause inclusion body hepatitis outbreaks in broiler and broiler breeder pullet flocks
Kelly et al. Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting
CA2646026C (en) Nucleic acid primers and probes for detecting human and avian influenza viruses
Levina et al. High antiviral effect of TiO2· PL–DNA nanocomposites targeted to conservative regions of (−) RNA and (+) RNA of influenza A virus in cell culture
JP2006512906A5 (cg-RX-API-DMAC7.html)
Conrardy et al. Molecular detection of adenoviruses, rhabdoviruses, and paramyxoviruses in bats from Kenya
JP2016533172A5 (cg-RX-API-DMAC7.html)
Ishida et al. Establishment of a reverse genetics system for influenza D virus
Schweiger et al. Reassortment between human A (H3N2) viruses is an important evolutionary mechanism
Broto et al. Type I interferon acts as a major barrier to the establishment of persistent infectious bursal disease virus infections
FI3800257T3 (fi) Pan-genotyyppisiä aineita influenssavirusta vastaan ja menetelmiä niiden käyttämiseksi
Bradfute The discovery and development of novel treatment strategies for filoviruses
US20160281089A1 (en) Prevention of viral infectivity
Wang et al. Increased substitution rate in H5N1 avian influenza viruses during mass vaccination of poultry
Giannecchini et al. Oligonucleotides derived from the packaging signal at the 5′ end of the viral PB2 segment specifically inhibit influenza virus in vitro
JP2023514576A5 (cg-RX-API-DMAC7.html)
Wang et al. Enhanced antiviral ability by a combination of zidovudine and short hairpin RNA targeting avian leukosis virus
Hartawan et al. Improving siRNA design targeting nucleoprotein gene as antiviral against the Indonesian H5N1 virus
Giannecchini et al. Packaging signals in the 5′-ends of influenza virus PA, PB1, and PB2 genes as potential targets to develop nucleic-acid based antiviral molecules
US10548915B2 (en) Combination therapy for EV71 infection
TW201834664A (zh) 抗病毒劑及治療病毒感染之方法
Heinrich et al. A short hairpin loop-structured oligodeoxynucleotide targeting the virion-associated RNase H of HIV inhibits HIV production in cell culture and in huPBL-SCID mice
Kwok et al. Inhibition of influenza A virus replication by short double-stranded oligodeoxynucleotides